InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo's most recent breakthroughs and provide a business update to potential investors at BOCEMb Noble Financial Capital Markets' Eight Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Wednesday, January 18th at 9:00 am EST.

At the time of the presentation, participants can view a live audio and high-definition video webcast of InVivo Therapeutics' presentation. A copy of the presentation materials will also be available through the Noble Financial websites: www.noblefcm.com, or www.BOCEM2012.com. InVivo Therapeutics recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also archived on InVivo Therapeutics' website for 90 days following the event.

The BOCEMb 2012 Equity Conference is sponsored by Noble Financial Capital Markets. The conference provides informational services and networking opportunities for public companies and investors. Noble Financial Capital Markets is an equity research driven, full-service, investment banking boutique focused on small-cap, emerging growth companies.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Media Contact:
Lisa Kornblatt
SS|PR
847-415-9330
lkornblatt@sspr.com